{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:00:27Z","timestamp":1780318827806,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["356069-09"],"award-info":[{"award-number":["356069-09"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["355912-11"],"award-info":[{"award-number":["355912-11"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003331","name":"Provincial Health Services Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vph.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T16:32:15Z","timestamp":1403541135000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats"],"prefix":"10.1016","volume":"62","author":[{"given":"Joanne Y.T.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.Y.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.06.003_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2009.12.016","article-title":"Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study","volume":"117","author":"Bresee","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.vph.2014.06.003_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.vph.2014.06.003_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vph.2014.06.003_bb0020","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vph.2014.06.003_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.06.003_bb0030","first-page":"26","article-title":"Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly","author":"Vieweg","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vph.2014.06.003_bb0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.vph.2014.06.003_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/JCP.0b013e3182a607dd","article-title":"Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility","volume":"34","author":"Procyshyn","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00004714-199812000-00011","article-title":"Prolongation of QT interval in isolated feline hearts by antipsychotic drugs","volume":"18","author":"Drici","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(98)00013-X","article-title":"Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers","volume":"7","author":"Studenik","year":"1999","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.vph.2014.06.003_bb0055","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bmj.325.7372.1070","article-title":"Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data","volume":"325","author":"Hennessy","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2014.06.003_bb0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-2007-1000124","article-title":"Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats","volume":"15","author":"Aygit","year":"1999","journal-title":"J Reconstr Microsurg"},{"key":"10.1016\/j.vph.2014.06.003_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(97)01242-9","article-title":"The antipsychotic drug sertindole is a specific inhibitor of alpha1a-adrenoceptors in rat mesenteric small arteries","volume":"336","author":"Ipsen","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-007-1064-9","article-title":"Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function","volume":"199","author":"Nourian","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vph.2014.06.003_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1345\/aph.17215","article-title":"Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy","volume":"33","author":"Markowitz","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.vph.2014.06.003_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.vph.2014.06.003_bb0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.vph.2014.06.003_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vph.2014.06.003_bb0095","doi-asserted-by":"crossref","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine","volume":"8","author":"Boyda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2014.06.003_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats","volume":"21","author":"Boyda","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","volume":"48","author":"Boyda","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.vph.2014.06.003_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.vph.2014.06.003_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1056-8719(00)00124-6","article-title":"Measurement of body venous tone","volume":"44","author":"Pang","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vph.2014.06.003_bb0120","first-page":"H823","article-title":"Total vascular pressure\u2013volume relationship in the conscious rat","volume":"238","author":"Yamamoto","year":"1980","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2014.06.003_bb0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.vph.2014.06.003_bb0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2007.11.027","article-title":"Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment","volume":"100","author":"Barr","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.vph.2014.06.003_bb0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1017\/S1355617712000343","article-title":"Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis","volume":"18","author":"Baitz","year":"2012","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.vph.2014.06.003_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2210-1-4","article-title":"Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats","author":"Vera","year":"2001","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0091270005283839","article-title":"Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers","volume":"46","author":"Markowitz","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0091270002042001013","article-title":"Hypotension and bradycardia in a healthy volunteer following a single 5mg dose of olanzapine","volume":"42","author":"Markowitz","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.0306-5251.2001.01448.x","article-title":"Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects","volume":"52","author":"Pretorius","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1020464017021","article-title":"Safety and tolerability: how do newer generation \u201catypical\u201d antipsychotics compare?","volume":"73","author":"Tandon","year":"2002","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.vph.2014.06.003_bb0165","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1742-1241.2009.02116.x","article-title":"Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania","volume":"63","author":"Chandrasena","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vph.2014.06.003_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccl.2012.09.003","article-title":"Confounders of vasovagal syncope: orthostatic hypotension","volume":"31","author":"Nwazue","year":"2013","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.vph.2014.06.003_bb0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1152\/advan.00114.2010","article-title":"Neural control of the circulation","volume":"35","author":"Thomas","year":"2011","journal-title":"Adv Physiol Educ"},{"key":"10.1016\/j.vph.2014.06.003_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1476-5381.1988.tb11401.x","article-title":"Effect of chlorpromazine on sympathetic neuroeffector transmission in the rabbit isolated pulmonary artery and aorta","volume":"93","author":"Nedergaard","year":"1988","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.vph.2014.06.003_bb0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.103.056184","article-title":"Increased reactivity of murine mesenteric veins to adrenergic agonists: functional evidence supporting increased alpha1-adrenoceptor reserve in veins compared with arteries","volume":"308","author":"Perez-Rivera","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vph.2014.06.003_bb0195","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-2999(90)90287-G","article-title":"Effects of alpha 1- and alpha 2-adrenoceptor antagonists on venous tone in conscious rats","volume":"182","author":"D'Oyley","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0200","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00213-014-3459-8","article-title":"Alpha2-adrenoceptors are targets for antipsychotic drugs","volume":"231","author":"Brosda","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vph.2014.06.003_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1476-5381.1986.tb10272.x","article-title":"The effects of noradrenaline, B-HT 920, methoxamine, angiotensin II and vasopressin on mean circulatory filling pressure in conscious rats","volume":"89","author":"Pang","year":"1986","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2012.06.011","article-title":"Pharmacological identification of the alpha(2)-adrenoceptor subtypes mediating the vasopressor responses to B-HT 933 in pithed rats","volume":"691","author":"Villamil-Hernandez","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0215","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/PL00004961","article-title":"Alpha 2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein","volume":"355","author":"Gavin","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vph.2014.06.003_bb0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1752-1947-5-189","article-title":"An unusual case of hypothermia associated with therapeutic doses of olanzapine: a case report","volume":"5","author":"Rasnayake","year":"2011","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.vph.2014.06.003_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1081\/CLT-120028741","article-title":"The clinical picture of olanzapine poisoning with special reference to fluctuating mental status","volume":"42","author":"Palenzona","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.vph.2014.06.003_bb0235","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/157488612804096605","article-title":"Nonfatal suicidal overdose of olanzapine in an adolescent","volume":"7","author":"Singh","year":"2012","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.vph.2014.06.003_bb0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e32805aedf5","article-title":"Olanzapine overdose: a series of analytically confirmed cases","volume":"22","author":"Morgan","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0245","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1192\/apt.9.6.414","article-title":"Psychotropic medication and the heart","volume":"9","author":"O'Brien","year":"2003","journal-title":"Adv Psychiatr Treat"},{"key":"10.1016\/j.vph.2014.06.003_bb0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vascn.2009.07.002","article-title":"Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates","volume":"60","author":"Guo","year":"2009","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vph.2014.06.003_bb0255","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00007.2009","article-title":"Sympathetic nervous system overactivity and its role in the development of cardiovascular disease","volume":"90","author":"Malpas","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vph.2014.06.003_bb0260","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1016\/j.ehjsup.2004.09.004","article-title":"Experimental models of heart failure","author":"Vanoli","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.06.003_bb0265","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","article-title":"Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database","volume":"36","author":"Poluzzi","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.vph.2014.06.003_bb0270","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.22.1.1.33496","article-title":"Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis","volume":"22","author":"Ellingrod","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.vph.2014.06.003_bb0280","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2010.10.014","article-title":"The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela","volume":"126","author":"Baptista","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.vph.2014.06.003_bb0285","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jpsychires.2009.01.010","article-title":"In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment","volume":"43","author":"Reaven","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.vph.2014.06.003_bb0290","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.pnpbp.2011.01.010","article-title":"Weight gain and ghrelin level after olanzapine monotherapy","volume":"35","author":"Chen","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.vph.2014.06.003_bb0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1471-4159.2011.07410.x","article-title":"Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin e(2) concentration in rat brain","volume":"119","author":"Cheon","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.vph.2014.06.003_bb0300","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain","volume":"551","author":"Patil","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2014.06.003_bb0305","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.vph.2014.06.003_bb0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145713000795","article-title":"Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats","volume":"17","author":"Boyda","year":"2014","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:21:20Z","timestamp":1538544080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1537189114001098"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.06.003","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}